News Archive

ISTH Invites Public Comment on Draft TTP Guidelines

The ISTH welcomes the public to comment on its draft recommendations for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP) via online survey only by October 21.

Answering TTP Foundation will submit feedback reviewed by a panel of patients and supporters. Clinicians, researchers, allied health professionals, policy makers, industry representatives, patients, caregivers, and other members of the public have been invited to contribute to this process.

Industry aTTP Patient Advisory Board Opportunity

A healthcare research firm is recruiting patients to assemble an advisory board of people living with an aTTP diagnosis. This advisory board will provide insight and feedback for the benefit of a particular pharmaceutical company. Participants will be compensated at a fair market value for their time.
 
For more information and for participation instructions click here.
Support Groups

Fall 2018 Ohio TTP & aHUS Support Group Meeting

The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.

Researcher's Work is Published

Answering TTP Foundation provided research grant funding to support Dr. Long Zheng which has resulted in two research papers on TTP. Together we are furthering the understanding and coming closer to a targeted treatment for TTP. Congratulations Dr. Long Zheng! And congratulations to all supporters of the Answering TTP Foundation.

hTTP Study Recruiting

A healthcare research firm is recruiting patients who have been diagnosed with hereditary (inherited) thrombotic thrombocytopenic purpura (hTTP). hTTP represents about 1% of  TTP cases and is characterized by inherited deficiency or abnormality of the ADAMTS 13 enzyme.

For more information and for participation instructions click here.

Pages